Saikosaponin A (Bupleurum Oleanane Triterpene Saponin · Hepatoprotective · Anti-inflammatory)

Compound	Saikosaponin A (Bupleurin A; Saikosaponin a)
Chemical class	Terpenoid — Triterpene Saponin (Oleanane-type; pentacyclic triterpene glycoside)
CAS	20736-09-8
Primary source	Bupleurum chinense (chai hu / Chinese thoroughwax, dried roots)
Key applications	Anti-inflammatory; hepatoprotective; immunomodulatory; anti-tumour; adaptogenic (HPA axis)
Claim strength	Moderate
Typical form	Bupleurum root extract standardised to saikosaponins (a, c, d mixture); saikosaponin A isolate
Buy from Herbuno	Request availability and bulk pricing →

Name origin: From Saikosaponin — saiko is the Japanese transliteration of “chai hu” (東胡, Chinese thoroughwax), the TCM name for Bupleurum root. Saikosaponin A (SSa) is the primary and most studied member of the saikosaponin family (A, B, C, D are the major members). The family consists of oleanane-type pentacyclic triterpene saponins — saikogenin A (the aglycone) linked to glucose and fucose sugar chains. SSa and SSd have similar and complementary pharmacological profiles; SSa is generally considered more potent for anti-inflammatory activity. Traditional TCM significance: Bupleurum (Chai Hu, literally “gathered wood”) is one of the most prescribed herbs in Traditional Chinese Medicine — used in classical formulas (Xiao Chai Hu Tang / Minor Bupleurum Decoction) for over 1,800 years to regulate the Shao Yang (half-exterior/half-interior) pattern — characterised by alternating fever and chills, dry throat, vomiting, and bitter taste. Modern interpretation maps these indications onto anti-inflammatory, hepatoprotective, and immunoregulatory pharmacology. Xiao Chai Hu Tang (Sho-saiko-to in Japanese Kampo) has been extensively researched, particularly in Japan, for hepatitis and liver cancer prevention. Commercial source: Not currently in the Herbuno catalogue. Contact Herbuno for Bupleurum extract availability.

---

Evidence for Saikosaponin A Applications

Anti-inflammatory — glucocorticoid-mimetic: SSa has glucocorticoid receptor-modulating activity — it potentiates glucocorticoid signalling and has cortisone-like anti-inflammatory effects without the systemic adverse effects of exogenous glucocorticoids at the doses studied. This mechanism is relevant to the traditional TCM concept of Bupleurum as a “liver-soothing” herb with HPA axis regulatory properties. Claim strength: Moderate (mechanism; animal; traditional).

Hepatoprotective — Sho-saiko-to evidence: The Japanese multicentre RCT of Sho-saiko-to (Xiao Chai Hu Tang) in chronic hepatitis C (n=260, 5 years) showed significant reduction in liver cancer development (from 18% to 6%) and improved liver function in treated patients. The active roles of saikosaponins in this hepatoprotective/anti-carcinogenic effect are supported by mechanistic studies. This represents one of the most important TCM clinical trials conducted. Claim strength: Moderate (compelling clinical; single large trial; preparation not SSa-specific).

Immunomodulatory and anti-infective: SSa modulates macrophage activation (both stimulating and dampening depending on dose and immune context), NK cell activity, and T-cell function. Some antiviral activity against influenza and herpes viruses in cell models. Claim strength: Moderate (in vitro; animal).

---

Frequently Asked Questions — Saikosaponin A

What is Xiao Chai Hu Tang (Sho-saiko-to)?
Xiao Chai Hu Tang (小柰胡湿) is one of the most famous classical Chinese medicine formulas — recorded in the Shang Han Lun (Treatise on Cold Damage, Zhang Zhongjing, ~200 CE). It contains seven herbs: Bupleurum (the primary herb), Scutellaria, ginger, ginseng, jujube, licorice, and Pinellia. The formula is the most prescribed traditional formula in Japan (Sho-saiko-to) and has been extensively studied for chronic hepatitis B and C. The 5-year Japanese RCT demonstrating reduction in liver cancer development is cited as evidence for Bupleurum’s hepatoprotective activity, though the formula effect is from all seven herbs combined.

Is SSa safe or are there toxicity concerns with Bupleurum?
Bupleurum preparations in Japan (Sho-saiko-to) have been associated with rare cases of interstitial pneumonitis — an immune-mediated lung reaction reported in approximately 1:1,000 to 1:10,000 patients using Sho-saiko-to in Japan, particularly in patients on interferon therapy for hepatitis C (the combination appears to potentiate immune lung reactions). This Sho-saiko-to + interferon combination is now contraindicated in Japan. Bupleurum alone at recommended doses has a generally favourable safety profile in historical TCM use. The saikosaponin-specific contribution to this interaction is not definitively established.

What is the difference between saikosaponins A, B, C, and D?
SSa and SSd are the primary bioactive saikosaponins with similar anti-inflammatory and hepatoprotective activity. SSb (a mixture of SSb1 and SSb2) has reportedly more potent anti-tumour activity but is less well-characterised. SSc has lower anti-inflammatory potency than SSa. Commercial Bupleurum extracts are typically standardised to total saikosaponin content (A + D combined, or A + C + D) by HPLC, not SSa specifically. The ratio of SSa/SSd in different Bupleurum species and growing regions varies, affecting the pharmacological character of preparations.

Can SSa be used for adrenal fatigue or HPA axis support?
SSa’s glucocorticoid receptor modulation and HPA axis regulatory activity in animal models provides some mechanistic basis for adaptogenic use — reducing excessive cortisol response to stress (like the better-studied adaptogens ashwagandha and Rhodiola) while potentially potentiating the anti-inflammatory effects of endogenous cortisol at sub-saturating receptor occupancy. Traditional use for “Shao Yang” pattern which involves HPA-adjacent symptoms (alternating fever/chills, fatigue) supports this framing. However, “adrenal fatigue” as a clinical entity is not recognised in Western medicine; these applications are in the adaptogenic supplement positioning context.

Related compounds: Ginsenoside Rb1, Glycyrrhizin, Boswellic Acid, Escin

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery